文献速递甲状腺疾病

DUOX2双等位基因突变致先天性甲减停用左甲状腺素后的临床结局

Clinical Outcomes of Congenital Hypothyroidism Due to DUOX2 Biallelic Mutations after Levothyroxine Withdrawal.
PubMed 文献 · Thyroid · 2025-09-08

再评估分为永久性甲减7/28(25%)、暂时性甲减6/28(21.4%)和高促甲状腺素血症15/28(53.6%),中位随访17.5个月。停药后多数患者甲状腺球蛋白和甲状腺体积增大,高促甲状腺素血症组44.4%在停药超过一年后促甲状腺素正常化。

要点

  • DUOX2双等位基因突变致CH患者中部分为暂时性甲减或高促甲状腺素血症。
  • 永久性甲减组2、3岁及停药前左甲状腺素剂量显著高于暂时性甲减组。
  • 停药后多数患者甲状腺球蛋白和甲状腺体积增大,需长期随访防代偿性增生。

核心结论

  • DUOX2双等位基因突变所致CH患者可表现为暂时性甲减或高促甲状腺素血症,并非均为永久性甲减。
  • 停药后多数患者出现甲状腺球蛋白和甲状腺体积增大,尤其高促甲状腺素血症组,部分可自行正常化。

研究设计与样本

  • 28例患者在3岁后停用左甲状腺素并进行前瞻性临床再评估,定期评估甲状腺功能以判断是否需重新治疗。

主要发现

  • 再评估患者分为永久性CH 7/28(25%)、暂时性CH 6/28(21.4%)和高促甲状腺素血症15/28(53.6%)。
  • 中位随访17.5个月(四分位距:8.5,29.25)。
  • 三组诊断时实验室检查无显著差异。
  • 暂时性CH组左甲状腺素剂量随年龄下降,永久性CH组保持稳定;2岁、3岁及停药前剂量永久性CH组显著高于暂时性CH组(p=0.027;p=0.003;p=0.025)。
  • 停药后多数患者(尤其高促甲状腺素血症组)甲状腺球蛋白水平和甲状腺体积增大并持续数月;高促甲状腺素血症组44.4%在停药超过一年后促甲状腺素正常化。

关键数值与推荐

  • 永久性CH组与暂时性CH组左甲状腺素剂量比较:2岁时p=0.027,3岁时p=0.003,停药前p=0.025。
  • 高促甲状腺素血症组停药超过一年后44.4%患者促甲状腺素水平正常化。

临床怎么用

  • 对DUOX2双等位基因突变致CH患者,3岁后可考虑停用左甲状腺素并定期评估甲状腺功能。
  • 停药后需监测甲状腺球蛋白和甲状腺体积,防止过度代偿性甲状腺增生。
  • 永久性CH组左甲状腺素剂量随年龄保持稳定,暂时性CH组剂量可逐渐下降,可作为鉴别参考。

局限性

  • 本研究未明确DUOX2残余酶活性与临床结局的相关性。
  • 样本量较小(28例再评估),随访时间中位17.5个月,长期结局需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: DUOX2 is a major cause of congenital hypothyroidism (CH) in Chinese patients, but clinical outcomes for those with biallelic DUOX2 mutations remain unclear. This study aimed to describe the clinical manifestations of CH due to DUOX2 defect. Methods: One hundred eighty-one patients with primary CH were recruited initially and were subjected to genetic screening. Patients with DUOX2 biallelic mutations were chosen. After 3 years of age, 28 patients underwent a prospective clinical reevaluation after levothyroxine (LT4) withdrawal. Subsequent periodic evaluation of thyroid function was executed to evaluate the necessity of LT4 retreatment. The medical histories of all patients before the age of three years were collected and analyzed. DUOX2 residual enzymatic activity was also calculated relative to clinical outcomes. Results: Twenty-eight patients who were reevaluated were divided into three groups: patients with permanent CH (PCH; 7/28 [25%]), patients with transient CH (TCH; 6/28 [21.4%]), and patients with hyperthyrotropinemia (15/28 [53.6%]). The median duration of follow-up was 17.5 months (interquartile range: 8.5, 29.25). The correlation between DUOX2 residual enzymatic activity and the clinical outcome of patients with CH with DUOX2 biallelic mutations was not clear in this study. No significant differences in laboratory findings at diagnosis were observed among the three groups. LT4 dose decreased with age in TCH but remained stable in PCH. Doses at ages 2, 3, and pre-withdrawal were significantly higher in PCH versus TCH (p = 0.027; p = 0.003; p = 0.025). After LT4 withdrawal, serum thyroglobulin levels and thyroid size increased in most patients (especially hyperthyrotropinemia group) and often persisted for months. Moreover, thyrotropin levels normalized in 44.4% of patients with hyperthyrotropinemia after more than one year off LT4. Conclusions: Some patients with CH and DUOX2 biallelic mutations may have TCH or hyperthyrotropinemia. These patients should undergo long-term follow-up to prevent excessive compensatory thyroid hyperplasia.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Sun F, Wan JP, Zhang NN, et al. Clinical Outcomes of Congenital Hypothyroidism Due to DUOX2 Biallelic Mutations after Levothyroxine Withdrawal. Thyroid. 2025. PMID: 40916794. doi:10.1177/10507256251372195

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。